HALOZYME THERAPEUTICS, INC. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

HALOZYME THERAPEUTICS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $1.40 billion for the year ending 2025.

  • HALOZYME THERAPEUTICS, INC. showed an increase of +37.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
  • XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 9 years of available data (2017 to 2025), HALOZYME THERAPEUTICS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 341.1%.
  • Historical annual values: Fiscal year 2025: $1.40 billion | Fiscal year 2024: $1.02 billion | Fiscal year 2023: $829.25 million | Fiscal year 2022: $660.12 million | Fiscal year 2021: $443.31 million | Fiscal year 2020: $267.59 million | Fiscal year 2019: $195.99 million | Fiscal year 2018: $151.86 million | Fiscal year 2017: $316.61 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: